Jaguar Health Announces Maturity Date Has Been Extended From June 30, 2025 To January 30, 2026 For ~$2.57M Aggregate Principal Amount Of Convertible Promissory Notes Originally Issued By Company As Part Of Previously Announced $3.448M Bridge Financing

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), announced today that the maturity date has been extended from June 30, 2025 to January 30, 2026 for approximately $2.57 million aggregate principal amount of convertible promissory notes originally issued by the Company as part of the previously announced $3.448 million bridge financing that closed on March 31, 2025. Prior to the extension, five investors converted $0.866 million (including accrued interest) of the original bridge financing into equity in the Company.

"We're very pleased with each of the participants in this bridge financing that agreed to the extension of the maturity date," said Lisa Conte, Jaguar's Founder and CEO. "Each of these investors is committed to helping provide the resources needed to support Jaguar's goal of forging corporate partnerships to bring in non-dilutive funding for the Company's three core development programs for crofelemer, our novel plant-based prescription medicine: our orphan disease intestinal failure program; our ongoing efforts to make crofelemer available for treatment of cancer therapy-related diarrhea (CTD) in patients with metastatic breast cancer receiving selected targeted therapies; and our ongoing development program to expand access for Canalevia® (crofelemer delayed-release tablets) in dogs from the conditional approval in chemotherapy-induced diarrhea to a potential global approval for acute general diarrhea."